Munich Re Specialty – North America Launches Life Science Liability Coverage

Expansion Enhances Healthcare Capabilities in High-growth Sector

06/12/2025

    alt txt

    properties.trackTitle

    properties.trackSubtitle

    0:00
    0:00

    Princeton, NJ – Munich Re Specialty-North America (MRS-NA) has launched a new Life Science business, expanding its capabilities in one of the fast-growing sectors of both specialty insurance and healthcare.

    Life science enterprises have unique exposures that require a risk management partner with broad relevant experience, claims expertise and financial stability. The new MRS-NA life science liability offering is designed for insureds in pharmaceuticals (branded, generic, prescription and OTC), clinical trials, medical devices, dietary supplements, contract services and animal health.

    James Craig, senior vice president and an underwriter with longtime experience in life sciences liability insurance, will lead the new business, which is part of the Healthcare group in Excess & Surplus Lines at MRS-NA.

    “As innovation accelerates across the life science industry, so does the complexity of risk,” says Craig. “Life science companies seek stability and expertise in their insurance partners to manage volatility and protect against litigation and product liability risks. Munich Re Specialty’s new product offering is a direct response to what we’ve heard from our broker partners looking for smarter, more flexible coverages tailored to the realities of today’s medical and biotech advancements.”

    MRS-NA’s life science liability solution will provide:

    • Medical product liability coverage for product defects, clinical trials and regulatory compliance
    • Errors & Omissions (E&O) for financial loss protection for losses related to errors, omissions or negligence
    • Premises liability to ensure the safety of visitors, contractors and employees at client locations
    • Cyber and tech E&O to protect companies’ digital presence, assets and reputation from harm
    • Medical professional liability for protection with medical malpractices risks

    The life science market is projected to grow with a compound annual growth rate of approximately 10% between 2024 and 2033.1 The addition of the life science team to the healthcare practice enables MRS-NA to be a single source for all the healthcare-related risks of insureds. MRS-NA also has an in-house team of professionals who provide strategic claims management and litigation expertise.

    “Our life science liability coverage is responsive to the real-world needs of these clients and is competitive in the marketplace,” said Liz Kramer, President, Excess & Surplus Lines, MRS-NA. “Munich Re Specialty saw an opportunity to serve this vital niche as well as expand the capabilities of our healthcare portfolio. We’re proud to offer a solution that gives life science companies the confidence to grow, innovate and bring their solutions safely to market.”

    The MRS-NA life science team will work with wholesalers and retailers to provide both primary and excess coverage, is non-admitted in all 50 states and is supported by the unmatched financial stability of the Munich Re Group.

    To learn more about MRS-NA Life Science capabilities, visit Life Science Liability.

    Munich Re Specialty–North America (MRS-NA) is a description for the insurance business operations of affiliated companies in the Munich Re Group that share a common directive to offer and deliver specialty property and casualty insurance products and services in North America. MRS-NA offers its clients innovative risk and claims solutions powered by advanced technology and analytics, superior service and enhanced responsiveness to clients’ needs.

    Munich Re is one of the world’s leading providers of reinsurance, primary insurance and insurance-related risk solutions. The Group consists of the reinsurance and ERGO business segments, as well as the asset management company MEAG. Munich Re is globally active and operates in all lines of the insurance business. Since it was founded in 1880, Munich Re has been known for its unrivalled risk-related expertise and its sound financial position. Munich Re leverages its strengths to promote its clients’ business interests and technological progress. Moreover, Munich Re develops covers for new risks such as rocket launches, renewable energies, cyber risks and artificial intelligence. In the 2024 financial year, Munich Re generated insurance revenue of €60.8bn and a net result of €5.7bn. The Munich Re Group employed about 44,000 people worldwide as of 31 December 2024.

    Disclaimer
    This media release contains forward-looking statements that are based on current assumptions and forecasts of the management of Munich Re. Known and unknown risks, uncertainties and other factors could lead to material differences between the forward-looking statements given here and the actual development, in particular the results, financial situation and performance of our Company. The Company assumes no liability to update these forward-looking statements or to make them conform to future events or developments.

    For further questions please contact:

    Heather Hardwick
    Heather Hardwick
    Media Specialist
    Ashleigh Lockhart
    Ashleigh Lockhart
    Media Relations North America